, Volume 181, Issue 3, pp 496–503 | Cite as

Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats

  • William E. FantegrossiEmail author
  • Andrew W. Harrington
  • Justin R. Eckler
  • Sadia Arshad
  • Richard A. Rabin
  • Jerrold C. Winter
  • Andrew Coop
  • Kenner C. Rice
  • James H. Woods
Original Investigation



Few studies have examined the effects of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in vivo.


2C-T-7 was tested in a drug-elicited head twitch assay in mice and in several drug discrimination assays in rats; 2C-T-7 was compared to the phenylisopropylamine hallucinogen R(−)-1-(2,5-dimethoxy-4-methylphenyl)-2aminopropane (DOM) in both assays, with or without pretreatment with the selective 5-HT2A antagonist (+)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidine-methanol (M100907). Finally, the affinity of 2C-T-7 for three distinct 5-HT receptors was determined in rat brain.


Drug-elicited head twitches were quantified for 10 min following administration of various doses of either 2C-T-7 or R(−)-DOM, with and without pretreatments of 0.01 mg/kg M100907. In rats trained to discriminate lysergic acid diethylamide (LSD), 2C-T-7 and R(−)-DOM were tested for generalization. In further studies, rats were trained to discriminate 2C-T-7 from saline, then challenged with 0.05 mg/kg M100907. In competition binding studies, the affinity of 2C-T-7 was assessed at 5-HT2A receptors, 5-HT1A receptors, and 5-HT2C receptors.


2C-T-7 and R(−)-DOM induced similar head twitch responses in the mouse that were antagonized by M100907. In the rat, 2C-T-7 produced an intermediate degree of generalization (75%) to the LSD cue and served as a discriminative stimulus; these interoceptive effects were attenuated by M100907. Finally, 2C-T-7 had nanomolar affinity for 5-HT2A and 5-HT2C receptors and lower affinity for 5-HT1A receptors.


2C-T-7 is effective in two rodent models of 5-HT2 agonist activity and has affinity at receptors relevant to hallucinogen effects. The effectiveness with which M100907 antagonizes the behavioral actions of 2C-T-7 strongly suggests that the 5-HT2A receptor is an important site of action for this compound.


2C-T-7 Hallucinogens Phenethylamines Drug discrimination Head twitch response 5-HT2A receptor Mice Rats 


  1. Aceto MD, Mckean DB, Pearl J (1969) Effects of opiates and opiate antagonists on the straub tail reaction in mice. Br J Pharmacol 36:239–255Google Scholar
  2. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21(2S):16S–23SPubMedGoogle Scholar
  3. Boulton CS, Handley SL (1973) Factors modifying the head-twitch response to 5-hydroxytryptophan. Psychopharmacologia 31(3):205–214CrossRefPubMedGoogle Scholar
  4. Brauer LH, Goudie AJ, de Wit H (1997) Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130:2–13CrossRefPubMedGoogle Scholar
  5. Brown JB (2002) Schedules of controlled substances: temporary placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine into Schedule I. Fed Regist 67(183):59163–59165Google Scholar
  6. Colpaert FC, Janssen PAJ (1983) The head twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 22(8):993–1000PubMedCrossRefGoogle Scholar
  7. Corne SJ, Pickering RW (1967) A possible correlation between drug-induced hallucinations in man and a behavioral response in mice. Psychopharmacologia 11:65–78CrossRefPubMedGoogle Scholar
  8. Corne SJ, Pickering RW, Warner BT (1963) A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol 20:106–120Google Scholar
  9. Darmani NA (1998) Cocaine and selective monoamine uptake blockers (sertraline, nisoxetine, and GBR 12935) prevent the d-fenfluramine-induced head-twitch response in mice. Pharmacol Biochem Behav 60(1):83–90CrossRefPubMedGoogle Scholar
  10. Darmani NA, Martin BR, Glennon RA (1990a) Withdrawal from chronic treatment with (±)-DOI causes supersensitivity to 5-HT2 receptor-induced head-twitch behavior in mice. Eur J Pharmacol 186:115–118CrossRefPubMedGoogle Scholar
  11. Darmani NA, Martin BR, Pandy U, Glennon RA (1990b) Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav 36(4):901–906CrossRefPubMedGoogle Scholar
  12. Darmani NA, Martin BR, Glennon RA (1992) Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. J Pharmacol Exp Ther 262(2):692–698PubMedGoogle Scholar
  13. Dave KD, Harvey JA, Aloyo VJ (2002) A novel behavioral model that discriminates between 5-HT2A and 5-HT2C receptor activation. Pharmacol Biochem Behav 72:371–378CrossRefPubMedGoogle Scholar
  14. de Boer D, Bosman I (2004) A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm World Sci 26(2):110–113CrossRefPubMedGoogle Scholar
  15. Dursun SM, Handley SL (1996) Similarities in the pharmacology of spontaneous and DOI-induced head-shakes suggest 5-HT2A receptors are active under physiological conditions. Psychopharmacology 128:198–205CrossRefPubMedGoogle Scholar
  16. Fantegrossi WE, Kilbourn ME, Woods JH (2004a) Actions of the 5-HT2A antagonist M100907 in serotonin-depleted mice. 2004 Experimental Biology meeting abstracts [accessed at]. FASEB J, 18, Abstract #637.2
  17. Fantegrossi WE, Kiessel CL, Leach PT, Van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH (2004b) Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology 173(3–4):270–277CrossRefPubMedGoogle Scholar
  18. Fiorella D, Palumbo PA, Rabin RA, Winter JC (1995a) The time-dependent stimulus effects of R(−)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents. Psychopharmacology 119:239–245PubMedCrossRefGoogle Scholar
  19. Fiorella D, Rabin RA, Winter JC (1995b) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis. Psychopharmacology 121:347–356PubMedCrossRefGoogle Scholar
  20. Fozard JR, Palfreyman MG (1979) Metoclopramide antagonism of 5-HT-induced “wet-dog” shake behavior in the rat. N-S Arch Pharmacol 307:135–142CrossRefGoogle Scholar
  21. Glennon RA, Young R, Jacyno JM, Slusher M, Rosecrans JA (1983a) DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol 86:453–459CrossRefPubMedGoogle Scholar
  22. Glennon RA, Rosecrans JA, Young R (1983b) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289–340PubMedCrossRefGoogle Scholar
  23. Goodwin GM, Green AR (1985) A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol 84(3):743–755PubMedGoogle Scholar
  24. Green AR, O'Shaughnessy K, Hammond M, Schachter M, Grahame-Smith DG (1983) Inhibition of 5-hydroxytryptamine-mediated behaviours by the putative 5-HT2 receptor antagonist pirenperone. Neuropharmacology 22:573–578PubMedCrossRefGoogle Scholar
  25. Handley SL, Singh L (1986) Neurotransmitters and shaking behavior: more than a “gut bath” for the brain. Trends Pharmacol Sci 7:324–328CrossRefGoogle Scholar
  26. Khorana N, Pullagurla MR, Dukat M, Young R, Glennon R (2004) Stimulus effects of three sulfur-containing psychoactive agents. Pharmacol Biochem Behav 78:821–826CrossRefPubMedGoogle Scholar
  27. Leonhart MM (2004) Schedules of controlled substances: placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule 1 of the controlled substances act. Fed Regist 69(53):12795–12797Google Scholar
  28. Lucki I, Nobler MS, Frazer A (1984) Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 228:133–139PubMedGoogle Scholar
  29. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181CrossRefPubMedGoogle Scholar
  30. Ortmann R, Biscoff S, Radeke E, Bueche O, Delini-Stula A (1982) Correlation between different measures of antiserotonin activity of drugs. Naunyn-Schmiedeberg's Arch Pharmacol 321:265–270CrossRefGoogle Scholar
  31. Peroutka SJ, Lebovitz RM, Snyder SH (1981) Two distinct central serotonin receptors with different physiological functions. Science (Wash DC) 212:827–829CrossRefGoogle Scholar
  32. Sadzot B, Baraban JM, Glennon RA, Lyon RA (1989) Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98(4):495–499CrossRefPubMedGoogle Scholar
  33. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994) Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: evidence for functional significance of receptor subtypes. Neurosci Biobehav Rev 18:355–372CrossRefPubMedGoogle Scholar
  34. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101–112PubMedGoogle Scholar
  35. Schuster C, Johanson C (1988) Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Colpaert F, Balster R (eds) Transduction mechanisms of drug stimuli. Springer, Berlin Heidelberg New York, pp 161–175Google Scholar
  36. Shulgin A, Shulgin A (1991) PIHKAL: a chemical love story. Transform Press, Berkley, pp 567–571Google Scholar
  37. Strassman RJ, Qualls CR, Berg LM (1996) Differential tolerance to biological and subjective effects of 4 closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry 39:784–795CrossRefPubMedGoogle Scholar
  38. Vollenweider FX (1998) Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 31:92–103PubMedCrossRefGoogle Scholar
  39. Winter JC (1978) Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine. J Pharmacol Exp Ther 204:416–423PubMedGoogle Scholar
  40. Winter JC, Rabin RA (1988) Interactions between serotonergic agonists and antagonists in rats trained with LSD as a discriminative stimulus. Pharmacol Biochem Behav 30:617–624CrossRefPubMedGoogle Scholar
  41. Winter JC, Eckler JR, Rabin RA (2004) Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology 172:233–240CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • William E. Fantegrossi
    • 1
    • 2
    Email author
  • Andrew W. Harrington
    • 2
  • Justin R. Eckler
    • 3
  • Sadia Arshad
    • 3
  • Richard A. Rabin
    • 3
  • Jerrold C. Winter
    • 3
  • Andrew Coop
    • 4
  • Kenner C. Rice
    • 5
  • James H. Woods
    • 2
  1. 1.Division of Neuroscience, Yerkes National Primate Research CenterEmory UniversityAtlantaUSA
  2. 2.Department of PharmacologyUniversity of Michigan Medical SchoolAnn ArborUSA
  3. 3.Department of Pharmacology, School of Medicine and Biomedical SciencesState University of New York at BuffaloBuffaloUSA
  4. 4.Department of Pharmaceutical SciencesUniversity of Maryland School of PharmacyBaltimoreUSA
  5. 5.Laboratory of Medicinal ChemistryNIDDK, National Institutes of HealthBethesdaUSA

Personalised recommendations